Truxima (rituximab-abbs) is not a chemotherapy drug, rather it is a biologic that is targeted toward specific antigens (proteins). In this case, Truxima targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Truxima forms a complex with the CD20 antigen which causes B-cell death (lysis). Most cases of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia arise from B cells. Truxima is usually used together with chemotherapy treatments.